Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154PR Newswire • 5 days ago
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate...
Share to Feed
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body...
StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN - Free Report) in a research note released on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company's...
StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN - Free Report) in a research report released on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical...
StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN Free Report) in a report published on Tuesday morning. The brokerage issued a sell rating on the specialty pharmaceutical...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 PR Newswire SALT LAKE CITY, March 25, 2024 Company anticipates...
StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN Get Free Report) in a research note issued on Monday. The brokerage set a sell rating on the specialty...